

Inno4Vac 1st Annual Meeting

5th – 6th October 2022

Palazzo del Rettorato, University of Siena

Via Banchi di Sotto 55, Siena, Italy

Day 1

Registration (in front of Room Aula Magna): 8:20 – 8:50

WP internal meetings (Rooms Aula Magna Storica)

Time		Topic	Who
08:15 – 09:00	45 min	WP13, 14, & 15 internal meetings (parallel)	ST3 WPs (lead by: Thomas Rudel (UWB), Nicole Engert (JUH), Puck van Kasteren (RIVM))

General Session 1 (Room Aula Magna)

Chairs: Sandra Morel (GSK) and Ole Olesen (EVI)

Time		Topic	Who
09:00 – 9:10	10 min	Welcome Address from the Rector of the University of Siena	Francesco Frati (Rector of the University of Siena)
09:10 – 09:20	10 min	Welcome and Introduction	Ole Olesen (EVI) and Donata Medaglini (UNISI) Rapporteur: Irina Meln (EVI)

09:20 – 09:35	15 min	IHI overview	Manuel De La Guia Solaz (IHI) Rapporteur: Irina Meln (EVI)
09:35 – 10:05	20 min 10 min	ST1 VAXPRED Update: Predict immunity Q&A	Gunnveig Grødeland (UiO), Guglielmo Roma (GSK) Rapporteur: Luisa Borgianni (SVA)
10:05 – 10:35	20 min 10 min	ST2 CHIMICHURRI Update: progress in the development of novel CHIM models for flu, RSV and clostridioides Q&A	Meta Roestenberg (LUMC), Jeanne Marie Devaster (GSK) Rapporteur: Nicoletta Corti (EVI)
10:35 – 10:40	5 min	Inno4Vac Group photo	
10:40 – 11:00	30 min	Coffee Break	
11:00 – 11:30	20 min 10 min	ST3 MERMAID Update: The steady but bendy road towards <i>in vitro</i> 3D mucosal infection and protection models Q&A	Cecile van Els (RIVM) Rapporteur: Kimberly Veenstra (EVI)
11:30 – 12:00	20 min 10 min	ST4 VAXinS Update: Progress of biomanufacturing modelling Q&A	Daniel Bracewell (UCL) , Eric Calvosa (SP) , Antonio Cardillo (GSK) Rapporteur: Reinhard Liebers (EVI)
12:00 – 12:30	30 min	Keynote lecture: The Miracle of COVID-19 Vaccines and the Trillion Dollar gap	Rino Rappuoli (GSK) Rapporteur: Luisa Borgianni (SVA)
12:30 – 13:30	60 min	Lunch	
13:30 – 17:00		ST1,2,3,4 parallel sessions (see below)	
17:00 – 18:00	60 min	Steering Committee (Closed session) incl. the GMP production issues (20 min)	ad-hoc expert Adrian Wildfire, SC members Rapporteur: Reinhard Liebers (EVI)
17:00 – 18:00	60 min	Networking with other participants	
19:00		Consortium Dinner – Ristorante Spadaforte, Piazza del Campo 13	

Parallel Session ST1 (Room Sala Riunioni)

Chair: Gunnveig Grødeland (UiO); Rapporteur: Luisa Borgianni (SVA)

Time		Topic	Who
13:30 – 15:00	90 min	Chair: Habib Bashour (UiO) Repertoire sequencing data in relation to GC model Original antigenic sin Interoperability and FAIR	Niklas Schwan and Amar Garg (HZI) Elias Tjärnhage (UiO) Artur Rocha (INESC TEC)
15:00 – 15:30	30 min	Coffee Break	
15:30 – 16:00	90 min	Chair: Alexandre Costa (INESC TEC) Balancing Uncertainty and Ambiguity to Deliver the Highest Value, On Time, and On Budget	Ademar Aguiar (INESC TEC)
16:15 – 17:00	45 min	Join ST2 WP8 & WP9 session (Room Aula Magna)	


Parallel Session ST2 (Room Aula Magna)

Chair: Meta Roestenberg (LUMC); Rapporteur: Nicoletta Corti (EVI)

Time		Topic	Who
13:30 – 13:40	10 min	ST2 Project Management: - Deliverables timeline & risks review - Communications/Gaps	Nicoletta Corti (EVI)



13:40 – 14:20	50 min (25 min each)	WP8 / WP9: <ul style="list-style-type: none"> – Summary of Workshops key points – Update on strain selection and manufacture of challenge agents – Updates on pre-existing immunity in population to candidate strains 	Rebecca J Cox (UiB), Othmar (NIBSC), Chris Chiu (ICL), Ab Osterhaus (TiHo)
14:20 – 15:00	40 min	WP11: Need for interaction with the authorities on CHIM trial acceptability <ul style="list-style-type: none"> - Trial start and data use 	Pieter Neels (IABS-EU), Jeanne-Marie Devaster (GSK), Rebecca J. Cox (UiB), Chris Chiu (ICL), Meta Roestenberg (LUMC), Silvia Aiolli (SP)
15:00 – 15:30	30 min	Coffee Break	
15:30 – 16:15	45 min	WP10: <i>C. difficile</i> clinical trials framework brainstorm	Meta Roestenberg (LUMC), Jeanne-Marie Devaster (GSK)
16:15 – 17:00	45 min	WP8 & WP9 jointly <ul style="list-style-type: none"> – Design of the first-in-human influenza & RSV clinical characterisation studies <ul style="list-style-type: none"> ○ dose escalation strategy & initial sampling ○ samples and timepoints for which immune assays 	Rebecca J. Cox (UiB), Chris Chiu (ICL), Ingrid de Visser (CHDR) ST3 members: Puck van Kasteren (RIVM), Kevin Buno (GSK) ST1 members joining
17:00 – 18:00	60 min	Networking	



Parallel Session ST3 (Room Aula Magna Storica)

Chair: Cecile van Els (RIVM), Rapporteur: Kimberly Veenstra (EVI)

Time		Topic	Who
13:30 – 13:50	20 min	WP14 (RESP) updates: “set the scene”, what has been completed, how did they progress in the plan they had, risks, next steps	Puck van Kasteren (RIVM)
13:50 – 14:10	20 min	WP13 (GI) updates: “set the scene”, what has been completed, how did they progress in the plan they had, risks, next steps	Nicole Engert (JUH)
14:10 – 14:30	20 min	WP15 (UV) updates: “set the scene”, what has been completed, how did they progress in the plan they had, risks, next steps	Thomas Rudel (UWB)
14:30 – 15:00	30 min	General Discussion: complexity of models, troubleshooting	all
15:00 – 15:30	30 min	Coffee Break	
15:30 – 16:00	30 min	WP12 (REG) Session: presentation and feedback from workshop	Katie Huber (PEI)
16:00 – 17:00	60 min	WP15 (UV) working discussion: success criteria, standards, technical roadmap, qualification, characterization, variability, standardization <i>*WP14 members to attend ST2 WP8/9 session from 16:15 – 17:00 in Aula Magna*</i>	Thomas Rudel (UWB), all
17:00– 18:00	60 min	Networking	

Parallel Session ST4 (Room Sala Consiliare)

Chair: Daniel Bracewell (UCL), Rapporteur: Reinhard Liebers (EVI)

Time		Topic	Who
13:30 – 13:40	10 min	ST4 Welcome, progress and gaps	Daniel Bracewell (UCL), Eric Calvosa (Sanofi), Antonio Cardillo (GSK)
13:40 – 13:50	10 min	ST4 Project Management: deliverables, timelines	Reinhard Liebers (EVI)
13:50 – 14:20	30 min	WP16 – Stability. Update on: <ul style="list-style-type: none"> - Accelerated predictive stability, release limits, robustness, necessary data, timelines, further topics - Dissemination, gaps, next steps 	Laurent Natalis (PLX), Didier Clenet (SP)
14:20 – 14:50	30 min	WP16 Discussion and prioritization	Speakers, all participants
14:50 – 15:00	10 min	(Backup time)	
15:00 – 15:30	30 min	Coffee Break	
15:30 – 15:55	25 min	WP17 – Bioprocess (upstream). Updates on compartment models (D17.1), computational fluid dynamics, kinetic models, reactor types, case studies, WP17 output for WP18, dissemination, gaps, next steps <ul style="list-style-type: none"> - Mechanical part - Metabolic part 	Krist V. Gernaey (DTU), Antonio Cardillo & Serena Rossi (GSK), Klaus Mauch (Yokogawa Insilico) Krist V. Gernaey (DTU) Klaus Mauch (Yokogawa Insilico)
15:55 – 16:15	20 min	WP17 Discussion and prioritization	
16:15 – 16:40	25 min	WP18 – Bioprocess (downstream): updates, dissemination, gaps, next steps	





Agenda of meeting



		<ul style="list-style-type: none">- 18a: Chromatography- 18b: Centrifugation	Kristian Meyer (MCT), Luca Nompri (GSK) Andrea Rayat (UCL), Eric Calvosa (SP), Daniel Bracewell (UCL)
16:40 – 17:00	20 min	WP18 Discussion and prioritization	
17:00		Wrap-up	Daniel Bracewell (UCL)
17:00 – 18:00	60 min	Networking	



Day 2

General Session 2 (Room Aula Magna)

Chairs: Clarisse Demont (SP) and Donata Medagliani (SVA)

Time		Topic	Who
08:00 – 11:45		ST1,2,3,4 parallel sessions (see below)	
11:50 – 12:20	30 min	Keynote Lecture: Harmonisation and qualification of assays to measure cell-mediated immune responses to influenza vaccines	Geert Leroux Roles (Ghent University) Rapporteur: Tiziana Spadafina (SVA)
12:30 – 13:30	60 min	Lunch	
13:30 –13:45	15 min	Data management	Donata Medagliani (UNISI) Rapporteur: Tiziana Spadafina (SVA)
13:45 –14:00	15 min	Regulatory: outcomes of 3 STs Regulatory workshops and future plans (5 min per Subtopic)	Pieter Neels (IABS-EU), Katie Huber (PEI) and Wim Van Molle (Sciensano) Rapporteur: Kimberly Veenstra (EVI)
14:00 –14:20	20 min	Intellectual property rights	Landry Cochard (GSK) Q&A Rapporteur: Debora Dominici (GSK)
14:20 – 14:35	15 min	Grant opportunities for Inno4Vac	Landry Cochard (GSK), Donata Medagliani (SVA), Ole Olesen (EVI) Rapporteur: Debora Dominici (GSK)
14:35 – 15:05	30 min	Identification and Prioritization of Gaps for each ST	Gunnveig Grødeland (UiO) Meta Roestenberg (LUMC) Cecile van Els (RIVM)



Agenda of meeting



			Eric Calvosa (SP) Rapporteur: Reinhard Liebers (EVI)
15:05 – 15:30	25 min	Coffee Break	
15:30 – 15:45	15 min	Approvals from General Assembly	Ole Olesen (EVI) Rapporteur: Irina Meln (EVI)
15:45 – 16:15	30 min	Feedback from SEAC	Geert Leroux-Roels (SEAC) Rapporteur: Tiziana Spadafina (SVA)
16:15 – 16:25	10 min	Deliverables and Milestones	Irina Meln (EVI) Rapporteur: Kimberly Veenstra (EVI)
16:25 – 16:45	20 min	Periodic reporting	Reinhard Liebers (EVI) Rapporteur: Irina Meln (EVI)
16:45 – 17:00	15 min	Communication activities	Kimberly Veenstra (EVI) Rapporteur: Reinhard Liebers (EVI)
17:00 – 17:20	20 min	Next Steps	Ole Olesen (EVI), Sandra Morel (GSK) Donata Medagliani (SVA) Rapporteur: Luisa Borgianni (SVA)
17:20 – 17:30	10 min	Wrap Up	Ole Olesen (EVI) Rapporteur: Luisa Borgianni (SVA)

Parallel Session ST1 (Room Sala Riunioni)

Chairs: Elias Tjärnhage (UiO) and Gunnveig Grødeland (UiO), Rapporteur: Luisa Borgianni (SVA)

Time		Topic	Who
09:30 – 10:30	60 min	Chair: Elias Tjärnhage (UiO) TCR repertoire mining Nature unraveled by its sequence	Nicolas De Neuter (GSK) Guglielmo Roma (GSK)
10:30 – 11:00	30 min	Coffee Break	
11:00 – 11:45	45 min	Chair: Gunnveig Grødeland (UiO) VAXPRED progression	Roundtable discussion - All participants
11:45 – 11:50	5 min	Return to General Session for Keynote Talk	

Parallel Session ST2 (Room Aula Magna)

Chair: Jeanne-Marie Devaster (GSK), Rapporteur: Nicoletta Corti (EVI)

Time		Topic	Who
08:00 – 08:45	45 min	Contributions discussion with ST2 EFPIA members (closed session)	Pieter Neels (IABS-EU), Meta Roestenberg (LUMC), Chris Chiu (ICL), Rebecca J Cix (UiB), Ole Olesen (EVI), EFPIA representatives ST2
08:45 – 09:45	60 min	WP6/WP11: Approach for Stakeholder workshops and Nairobi Conference	Nicoletta Corti (EVI), Pieter Neels (IABS-EU), ALL
09:45 – 10:00	15 min	WP7: Demo of machine-operable platform for data sharing	M.Roestenberg (LUMC)
10:30 – 11:00	30 min	Coffee Break	

11:00 – 11:45	45 min	Integration of ST2/ST3: RSV, Flu viral strains synergies <i>ST3 goes to the room Aula Magna</i>	Rebecca J Cox (UiB), Christopher Chiu (ICL), Othmar Engelhardt (NIBSC) WP14 (RESP) and WP8/9 (Flu / RSV)
11:00 – 11:45		Integration of ST2/ST3: in depth discussion, regulatory discussion <i>ST2 goes to room Aula Magna Storica</i>	Meta Roestenberg (LUMC) WP13 (GI) and WP10 (C. diff)
11:45		Return to General Session for Keynote Talk	

Parallel Session ST3 (Room Aula Magna Storica)

Chair: Cecile van Els (RIVM), Rapporteur: Kimberly Veenstra (EVI)

Time		Topic	Who
08:00 – 9:00	60 min	WP13 (GI) working discussion: success criteria, standards, technical roadmap, qualification, characterization, variability, standardization	Nicole Engert (JUH), Nick Jinks (UoN)
9:00 – 10:00	60 min	WP14 (RESP) working discussion: success criteria, standards, technical roadmap, qualification, characterization, variability, standardization	Kevin Buno (GSK), all
10:00 – 10:30	30 min	WP discussions: internal debrief	all
10:30 – 11:00	30 min	Coffee Break	
11:00 – 11:45	45 min	Integration of ST2/ST3: RSV, Flu viral strains <i>ST3 goes to the room Aula Magna</i>	WP14 RESP: Puck van Kasteren (RIVM), Kevin Buno (GSK), (Simon Jochems and/or Anke Huckride possibly online) and WP8/9 (Flu / RSV)

11:00 – 11:45		Integration of ST2/ST3: in depth discussion, regulatory discussion <i>ST2 goes to room Aula Magna Storica</i>	WP13 GI: Nicole Engert, Valentin Wegner (JUH) and WP10 (C. diff)
11:45		Return to General Session for Keynote Talk	

Parallel Session ST4 (Room Sala Consiliare)

Chair: Daniel Bracewell (UCL), Rapporteur: Reinhard Liebers (EVI)

Time		Topic	Who
08:00 – 08:15	15 min	CADET introduction and its role as integration tool for (all) models	Eric von Lieres (FZJ)
08:15 – 08:35	20 min	Discussion on integrating WP16, WP17, WP18	WP16/17/18 speakers, all participants
08:35 – 08:55	20 min	WP19: Validation. Initiation, proof of concept for stability model predictive value (D19.1), targets for validation of WP17 and WP18, dissemination, gaps, next steps	Daniel Bracewell (UCL), leaders and speakers of WP17 and WP18
08:55 – 09:10	15 min	WP19 Discussion and prioritization	Speakers, all participants
09:10 – 09:30	20 min	Opportunities to deploy control	John Bagterp Jørgensen (2c)
09:30 – 09:50	20 min	WP20 Regulatory. Workshop outcome, dissemination, gaps, and next steps: from models to showcases	Wim Van Molle (Sciensano), Irina Meln (EVI)
09:50 – 10:15	25 min	WP20 Discussion and prioritization	
10:15 – 10:30	15 min	Identification and Prioritization of Gaps for the afternoon General Session 2	Eric Calvosa (SP)



Agenda of meeting



		Final discussion and wrap-up	
10:30 – 11:00	30 min	Coffee Break	
11:00 – 11:45	45 min	CADET Demonstration and Q&A	Johannes Schmölder (FZJ)
11:45		Return to General Session for Keynote Talk	



Participants

Last Name	First Name	Organization	Organization (acronym)	ST
Bagtap Jorgensen	John	2-control ApS	2control	4
Crul	Cynthia	Academisch Ziekenhuis Leiden	LUMC	2
Roestenberg	Meta	Academisch Ziekenhuis Leiden	LUMC	2
Smits	Wiep Klaas	Academisch Ziekenhuis Leiden	LUMC	2
Neels	Pieter	Association Internationale De Standardisation Biologique Pour L'Europe	IABS-EU	2
Gomes	Gabriela	Caparica Faculdade de Ciencias e Tecnologia da Universidade Nova de Lisboa	NOVAIDFCT	2
Melber	Karl	CUREVAC	Curevac	3
Srivastava	Barkha	CUREVAC	Curevac	3
Gernaey	Krist	Danmarks Tekniske Universitet	DTU	4
Wagner-Zafirov	Dorottya Sarolta	Danmarks Tekniske Universitet	DTU	4
Liu	Hui-Yu	Eberhard Karls Universitaet Tuebingen	EKUT	3
Lelieveld	Stefan	ENPICOM	ENPICOM	1
van den Ham	Henk-Jan	ENPICOM	ENPICOM	1
Corti	Nicoletta	European Vaccine Initiative	EVI	2
Liebers	Reinhard	European Vaccine Initiative	EVI	4
Meln	Irina	European Vaccine Initiative	EVI	all



Agenda of meeting



Olesen	Ole	European Vaccine Initiative	EVI	all
Veenstra	Kimberly	European Vaccine Initiative	EVI	3
Schmoelder	Johannes	Forschungszentrum Jülich	FZ	4
Buno	Kevin	GlaxoSmithKline Biologicals	GSK	3
Burny	Wivine	GlaxoSmithKline Biologicals	GSK	2
Campa	Cristiana	GlaxoSmithKline Biologicals	GSK	2
Cardillo	Antonio G.	GlaxoSmithKline Biologicals	GSK	4
Carryn	Stephane	GlaxoSmithKline Biologicals	GSK	2
Castado	Cindy	GlaxoSmithKline Biologicals	GSK	
Cecchi	Raffaella	GlaxoSmithKline Biologicals	GSK	
Cochard	Landry	GlaxoSmithKline Biologicals	GSK	all
Dasyam	Dileep	GlaxoSmithKline Biologicals	GSK	2
De Neuter	Nicolas	GlaxoSmithKline Biologicals	GSK	1
de Wergifosse	Bertrand	GlaxoSmithKline Biologicals	GSK	
Del Giudice	Giuseppe	GlaxoSmithKline Biologicals	GSK	
Delany	Isabel	GlaxoSmithKline Biologicals	GSK	3
Devaster	Jeanne-Marie	GlaxoSmithKline Biologicals	GSK	2
Dominici	Debora	GlaxoSmithKline Biologicals	GSK	all
Egar	Jeanne	GlaxoSmithKline Biologicals	GSK	
Elias	George	GlaxoSmithKline Biologicals	GSK	1



Agenda of meeting



Haj-Ali Saflo	Okba	GlaxoSmithKline Biologicals	GSK	
Hassan	Khaole	GlaxoSmithKline Biologicals	GSK	2
Morel	Sandra	GlaxoSmithKline Biologicals	GSK	all
Nompari	Luca	GlaxoSmithKline Biologicals	GSK	4
Roma	Guglielmo	GlaxoSmithKline Biologicals	GSK	1
Rossi	Serena	GlaxoSmithKline Biologicals	GSK	4
Siena	Emilio	GlaxoSmithKline Biologicals	GSK	
Temmerman	Stephane	GlaxoSmithKline Biologicals	GSK	3
Toffalini	Federica	GlaxoSmithKline Biologicals	GSK	all
Vanloubbeeck	Yannick	GlaxoSmithKline Biologicals	GSK	all
Kalamba Arachchi	Kavishna Ranmali	Goeteborgs Universitet	GU	3
Harandi	Ali	Goeteborgs Universitet	GU	3
Schwan	Niklas	Helmholtz-Zentrum Für Infektionsforschung	HZI	
Ascough	Stephanie	Imperial College London	Imperial	2
Chiu	Chris	Imperial College London	Imperial	2
Papargyris	Loukas	Imperial College London	Imperial	2
Aguiar	Ademar	Instituto De Engenharia de Sistemas E Computadores, Tecnologia E Ciência	INESC TEC	1
Costa	Alexandre	Instituto De Engenharia de Sistemas E Computadores, Tecnologia E Ciência	INESC TEC	1
Rocha	Artur	Instituto De Engenharia de Sistemas E Computadores, Tecnologia E Ciência	INESC TEC	1
Kessie	David	Julius-Maximilians-Universität Würzburg	UWB	3



Agenda of meeting



Rudel	Thomas	Julius-Maximilians-Universitat Wurzburg	UWB	3
Nilsson	Bernt	Lunds Universitet	LU	4
Meyer	Kristian	MCT Bioseparation	MCT	4
Engelhardt	Othmar	Medicines and Healthcare Products Regulatory Agency	NIBSC	2
Waldock	Joanna	Medicines and Healthcare Products Regulatory Agency	NIBSC	2
Ben Brahim	Ibtissem	Paul-Ehrlich-Institut	PEI	3
Blissenbach	Birgit	Paul-Ehrlich-Institut	PEI	2
Huber	Karen	Paul-Ehrlich-Institut	PEI	3
Krut	Oleg	Paul-Ehrlich-Institut	PEI	2
Forestieri	Caroline	Pharmalex Belgium	Pharmalex	4
Natalis	Laurent	Pharmalex Belgium	Pharmalex	4
Koutstaal	Rosanne	Rijksinstituut voor Volksgezondheid en Milieu	RIVM	3
van Els	Cecile	Rijksinstituut voor Volksgezondheid en Milieu	RIVM	3
van Kasteren	Puck	Rijksinstituut voor Volksgezondheid en Milieu	RIVM	3
Vandebriel	Rob	Rijksinstituut voor Volksgezondheid en Milieu	RIVM	3
Aiolfi	Silvia	Sanofi Pasteur	SP	2
Calvosa	Eric	Sanofi Pasteur	SP	4
Clenet	Didier	Sanofi Pasteur	SP	4
Demont	Clarisse	Sanofi Pasteur	SP	2
Reveneau	Nathalie	Sanofi Pasteur	SP	3



Agenda of meeting



Sridhar	Saranya	Sanofi Pasteur	SP	2
Vernhes	Charlotte	Sanofi Pasteur	SP	
Tesolin	Lorenzo	SCIENSANO	Sciensano	3
Van Molle	Wim	SCIENSANO	Sciensano	2, 4
Borgianni	Luisa	Sclavo Vaccines Association	SVA	1, 2, 3
Spadafina	Tiziana	Sclavo Vaccines Association	SVA	all
de Visser-Kamerling	Ingrid	Stichting Centre For Human Drug Research	CHDR	2
Osterhaus	Albert	Stiftung Tieraerztliche Hochschule Hannover	TiHo	2
Rimmelzwaan	Guus	Stiftung Tieraerztliche Hochschule Hannover	TiHO	2
Walter	Elke	TAKEDA Pharmaceuticals International	Takeda	3
Jinks	Nicholas	The University of Nottingham	UoN	3
Ciabattini	Annalisa	Universita Degli Studi di Siena	UNISI	3
Lucchesi	Simone	Universita Degli Studi di Siena	UNISI	2
Medaglini	Donata	Universita Degli Studi di Siena, Sclavo Vaccines Association	UNISI, SVA	all
Montesi	Giorgio	Universita Degli Studi di Siena	UNISI	2
Pettini	Elena	Universita Degli Studi di Siena	UNISI	3
Ricci	Susanna	Universita Degli Studi di Siena	UNISI	3
Santoro	Francesco	Universita Degli Studi di Siena	UNISI	2
Engert	Nicole	Universitaetsklinikum Jena	JUH	3
Koceva	Hristina	Universitaetsklinikum Jena	JUH	3

Wegner	Valentin	Universitaetsklinikum Jena	JUH	3
Sijts	Alice	Universiteit Utrecht	UU	3
Cox	Rebecca	Universitetet i Bergen	UiB	2
Ekanger	Camilla	Universitetet i Bergen	UiB	3
Jalloh	Sarah	Universitetet i Bergen	UiB	
Zhou	Fan	Universitetet i Bergen	UiB	2
Bashour	Habib	Universitetet i Oslo	UiO	1
de Matos Kasahara	Taissa	Universitetet i Oslo	UiO	1
Greiff	Victor	Universitetet i Oslo	UiO	1
Grodeland	Gunnveig	Universitetet i Oslo	UiO	1
Rawat	Puneet	Universitetet i Oslo	UiO	1
Tjarnhage	Elias	Universitetet i Oslo	UiO	1
Bracewell	Daniel	University College London	UCL	4
Vershield	Maria	Universitat zu Koln	UZK	2
Jeeninga	Rienk	Viroclinics Biosciences	Viroclinics	2
Stadler	Konrad	Viroclinics Biosciences	Viroclinics	2
Piccini	Giulia	VISMEDERI	Vismederi	3
Mauch	Klaus	Yokogawa Insilico Biotechnology	Yokogawa	4



Agenda of meeting



External Participants

Last Name	First Name	Organization	Organization (acronym)	Role
Leroux-Roels	Geert	Universiteit Gent	UGent	SEAC member, keynote
De La Guia Solaz	Manuel	Innovative Health Initiative	IHI	IHI presentation
Rappuoli	Rino	GlaxoSmithKline Biologicals	GSK	keynote
Wildfire	Adrian	CHIMunomics	CHIMunomics	external guest ST2

